Anticoagulation pharmacology distinguishes two mechanistically distinct drug classes by their point of action in the coagulation cascade: parenteral heparins (unfractionated heparin and low-molecular-weight heparin such as enoxaparin) potentiate antithrombin to inhibit thrombin-mediated clot propagation with immediate onset, while the oral coumarin warfarin antagonizes vitamin K to suppress hepatic synthesis of vitamin K-dependent clotting factors, producing a delayed onset of three to five days. Because each class acts on a different limb of the cascade, each is monitored by a different coagulation assay — aPTT for heparin, PT/INR for warfarin — and each has a mechanism-specific reversal agent, protamine sulfate for heparin and vitamin K for warfarin. Within pharmacology and hematologic therapeutics, this pairing illustrates the general principle that a drug's monitoring parameter and its antidote are both derived from its mechanism of action, and that anticoagulants prevent thrombus formation and extension without lysing existing thrombi.
Anticoagulation pharmacology distinguishes two mechanistically distinct drug classes by their point of action in the coagulation cascade: parenteral heparins (unfractionated heparin and low-molecular…